Everbrite Technology Co., Ltd. (4523)

Overview

Eisai Co., Ltd. is a prominent pharmaceutical company based in Tokyo, Japan, with a rich history dating back to its incorporation in 1941. Originally founded as Nihon Eisai Co., Ltd., the company underwent a name change to Eisai Co., Ltd. in 1955. It has established itself as a leader in the pharmaceutical field through its extensive research and development, manufacturing, and the sale and international trade of pharmaceuticals. Eisai's mission revolves around contributing to the health and welfare of people worldwide by providing innovative and effective medications for various medical conditions.

Products and Services

• Dayvigo

  Dayvigo is marketed by Eisai for the treatment of insomnia, aiding individuals who struggle with sleep disorders to achieve a better night's rest.

• Lenvima

  An anticancer agent and molecular targeted medicine, Lenvima is used for the treatment of thyroid cancer, renal cell carcinoma in combination with everolimus, and hepatocellular carcinoma, making it a versatile option in cancer therapy.

• Methycobal

  This product is aimed at treating peripheral neuropathy by aiding nerve regeneration and alleviating symptoms of nerve damage.

• Halaven

  Halaven is another anticancer agent in Eisai's portfolio, specifically developed for the treatment of breast cancer, highlighting the company's focus on innovative cancer treatments.

• Jyseleca

  A janus kinase inhibitor, Jyseleca represents Eisai's foray into the treatment of autoimmune diseases, aiming to provide relief for those suffering from such conditions.

• Elental

  This product is a branched-chain amino acid preparation, designed to support patients who require nutritional management in the context of medical conditions.

• Goofice and Movicol

  Both products cater to individuals suffering from chronic constipation, offering solutions that promote bowel movements and relieve discomfort.

• Fycompa

  As an antiepileptic agent, Fycompa underscores Eisai's commitment to addressing neurological disorders by helping to manage seizures in patients with epilepsy.

• Pariet

  Pariet acts as a proton-pump inhibitor, offering relief to those suffering from acid reflux and related conditions by reducing stomach acid production.

• Aricept

  Targeted towards the treatment of Alzheimer's disease and dementia with Lewy bodies, Aricept is pivotal in Eisai's neurological portfolio, aimed at improving memory and cognitive function.

• Chocola BB Plus

  This vitamin B2 preparation is designed to address deficiencies and support overall health, reflecting Eisai's dedication to preventative care and wellness.